Is there a dose response relationship for clodronate in the treatment of tumour induced hypercalcaemia?

Eighty-six patients with tumour induced hypercalcaemia were randomised to 600, 900, 1200 or 1500 mg of intravenous clodronate, according to post hydration serum calcium levels. Sixty-seven were evaluable for response. The overall response rate was 49.3% (95% CI: 36.8–61.8) with no significant differ...

Descripción completa

Detalles Bibliográficos
Autores principales: Shah, S, Hardy, J, Rees, E, Ling, J, Gwilliam, B, Davis, C, Broadley, K, A'Hern, R
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2002
Materias:
Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2375352/
https://www.ncbi.nlm.nih.gov/pubmed/11953878
http://dx.doi.org/10.1038/sj.bjc.6600249
Descripción
Sumario:Eighty-six patients with tumour induced hypercalcaemia were randomised to 600, 900, 1200 or 1500 mg of intravenous clodronate, according to post hydration serum calcium levels. Sixty-seven were evaluable for response. The overall response rate was 49.3% (95% CI: 36.8–61.8) with no significant difference in response rates, i.e. achievement of normocalcaemia at days 6–9 (corrected serum calcium ⩽2.6 mmol l(−1)) across all groups. British Journal of Cancer (2002) 86, 1235–1237. DOI: 10.1038/sj/bjc/6600249 www.bjcancer.com © 2002 Cancer Research UK

Ejemplares similares